Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 13

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 13
---
 financial statements have been adjusted, on a retroactive basis, to reflect the Reverse Stock Splits.

Business Combination
Agreement - On June 6, 2023, CERo Therapeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September
23, 2016, and based in South San Francisco, California, entered into a Business Combination Agreement and Plan of Reorganization (the
“BCA”) with PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX, with the surviving operating entity being
named CERo Therapeutics Holdings, Inc., and such transaction, the “Business Combination” or “Merger”.

Going concern –
The accompanying unaudited condensed consolidated financial statements
have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction
of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability
to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely
basis. As of September 30, 2025, the Company reported approximately $1.9 million of cash and cash equivalents, with an accumulated deficit
of approximately $86.3 million. On February 5, 2025, we entered into a securities purchase agreement (the “SPA”), with participation
from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551
shares of our common stock or common stock equivalents in lieu thereof; and (ii) common warrants to purchase up to 127,551 shares of common
stock, at a combined public offering price of $39.20 per share and warrant. In connection with this offering, we received net proceeds
of approximately $4.2 million. Additionally, during the nine months ended September 30, 2025, we received net proceeds from the exercise
of the remaining Series A Preferred Warrants, the collection of stock subscriptions receivable and ELOC fundings of approximately $4.2
million. Furthermore, during the nine months ended September 30, 2025, we received net proceeds from the sales of Series D Preferred Stock
of approximately $2.6 million. Additional funds are necessary to maintain current operations and to continue R&D activities. However,
there can be no assurance that sufficient funding will be available to allow the Company to successfully